Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: wolfdog2 who wrote (1495)	10/22/1998 9:28:00 AM
From: christopher	Read Replies (1) \| Respond to of 2173

Anergen (ANRG) was a good example of a dead cat bounce last week...

To: wolfdog2 who wrote (1495)	10/22/1998 8:59:00 PM
From: arnie h	Read Replies (1) \| Respond to of 2173

Jerry: Here's a company that spent several hundred million dollars on research and is now worth about $15M at today's price. Is it possible these folks don't know how to do clinical trials and someone who does might find value in their scientific estate? The price seems right,if so. Anybody have a feel for whether there is any value to their science and proprietary technology? As I recall they have some 20 or so issued patents. The nausea and other side effects found in the phase 3 studies were not mentioned in the phase 2 results which is one of the things that prompts the above question. There's an old saying that "some days you get the bear and other days the bear gets you". The bear won on this one. Arnie